Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.33 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13820355 | 0.90 | KDM4E (0.33) | ALOX5 | |
| SCHEMBL16472899 | 0.85 | CYP11B1 (0.42) | CYP11B1GPR84CYP11B2HIPK2MAPT | |
| SCHEMBL16472895 | 0.85 | CYP11B1 (0.42) | CYP11B1GPR84CYP11B2HIPK2MAPT | |
| SCHEMBL13820440 | 0.82 | CYP11B1 (0.45) | CYP11B1GPR84CYP11B2HIPK2MAPT | |
| SCHEMBL15681305 | 0.81 | L3MBTL1 (0.42) | MAPTRAB9A | |
| SCHEMBL13820431 | 0.80 | CYP11B1 (0.42) | CYP11B1GPR84CYP11B2MAPT | |
| SCHEMBL13820580 | 0.79 | KDM4E (0.32) | — | |
| SCHEMBL16472912 | 0.79 | KDM4E (0.35) | CYP11B2MAPTKCNH2AOC3NPC1 | |
| SCHEMBL21180543 | 0.77 | L3MBTL1 (0.40) | MAPTRAB9AALOX5 | |
| SCHEMBL21180579 | 0.77 | L3MBTL1 (0.40) | MAPTRAB9AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120286251-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| US-20120286251-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120286251-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, LEF1, OR51E2 | CYP11B1 613/4885GPR84 1320/4885CYP11B2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.